Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis C Virus in patients with inherited bleeding disorders

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Patients with inherited bleeding disorders have a high prevalence of coinfection with hepatitis C virus (HCV) and HIV. HCV-related liver disease remains a significant contributor to morbidity and mortality in this patient population, and the rate of liver disease progression may be accelerated by HIV coinfection. Although treatment for HCV monoinfection has achieved relative success in other patient cohorts, rates of sustained virologic response for both monoinfected and HCV/HIV-coinfected hemophiliacs lag behind. Few studies have investigated the mechanisms underlying these lower response rates. This article describes the burden of HCV infection in hemophiliacs, explores viral and host factors that may mediate liver disease progression and response to treatment, outlines the role of biopsy in patients with bleeding disorders, and summarizes HCV treatment trials to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Troisi CL, Hollinger FB, Hoots WK, et al.: A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993, 81:412–418.

    PubMed  CAS  Google Scholar 

  2. Aach RD, Szmuness W, Mosley JW, et al.: Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 1981, 304:989–994.

    Article  PubMed  CAS  Google Scholar 

  3. Goedert JJ, Eyster ME, Lederman MM, et al.: End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002, 100:1584–1589. This study followed over 1800 HCV-infected hemophiliacs for 16 years to examine the associations between age, HBV coinfection, and HIV coinfection on the risk of HCV-related ESLD. Nearly 60% of subjects were coinfected with HIV, and HIV was associated with a significantly increased risk of HCV-related ESLD.

    PubMed  CAS  Google Scholar 

  4. Goedert JJ, Brown DL, Hoots K, Sherman KE: Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004, 10(suppl 4):205–210. The authors examine the prevalence and consequences of viral hepatitis and HIV in hemophiliacs in the post-HAART era. In the years 2001 to 2003, nearly 30% of hemophiliacs were coinfected with HCV and HIV, and approximately 5% with HCV and HBV. Liver-related morbidity and mortality remain a significant concern in this population.

    Article  PubMed  Google Scholar 

  5. Soucie JM, Nuss R, Evatt B, et al.: Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000, 96:437–442.

    PubMed  CAS  Google Scholar 

  6. Eyster ME, Schaefer JH, Ragni MV, et al.: Changing causes of death in Pennsylvania’s hemophiliacs 1976 to 1991: impact of liver disease and acquired immunodeficiency syndrome. Blood 1992, 79:2494–2495.

    PubMed  CAS  Google Scholar 

  7. Ragni MV, Belle SH: Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001, 183:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  8. Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology 2000, 31:1014–018.

    Article  PubMed  Google Scholar 

  9. Poynard T, Bedossa P, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Lancet 1997, 33:562–569.

    Google Scholar 

  10. Koziel MJ: The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997, 4:31–41.

    PubMed  Google Scholar 

  11. Qin H, Shire NJ, Keenan ED, et al.: HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2004, 105:533–541.

    Article  PubMed  CAS  Google Scholar 

  12. Laskus T, Wilkinson J, Gallegos-Orozco JF, et al.: Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004, 127:764–776.

    Article  PubMed  CAS  Google Scholar 

  13. Tagariello G, Gerotto M, Pontisso P, et al.: Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. Haemophilia 2004, 10:81–86.

    Article  PubMed  CAS  Google Scholar 

  14. Sebagh M, Rifai K, Feray C, et al.: All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003, 37:1293–1301.

    Article  PubMed  Google Scholar 

  15. Ghany MG, Kleiner DE, Alter H, et al.: Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003, 124:97–104.

    Article  PubMed  Google Scholar 

  16. Eyster ME, Sherman KE, Goedert JJ, et al.: Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999, 179:1062–1069.

    Article  PubMed  CAS  Google Scholar 

  17. Krarup HB, Moller JM, Christensen PB, et al.: Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 2000, 7:435–439.

    Article  PubMed  CAS  Google Scholar 

  18. Daar ES, Lynn H, Donfield S, et al.: Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001, 26:466–472.

    PubMed  CAS  Google Scholar 

  19. Daar ES, Lynn H, Donfield S, et al.: Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001, 183:589–595.

    Article  PubMed  CAS  Google Scholar 

  20. Sherman KE, Shire NJ, Rouster SD, et al.: Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virusinfected patients. Gastroenterology 2005, 128:313–327.

    Article  PubMed  CAS  Google Scholar 

  21. Ghio M, Contini P, Ottonello L, et al.: Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003, 89:365–373.

    PubMed  CAS  Google Scholar 

  22. Matsutani T, Sakurai Y, Yoshioka T, et al.: Replacement therapy with plasma-derived factor VIII concentrates induces skew in T-cell receptor usage and clonal expansion of CD8+ T-cell in HIV-seronegative hemophilia patients. Thromb Haemost 2003, 90:279–292.

    PubMed  CAS  Google Scholar 

  23. Meijer K, Van Der Meer J, Smit JW, et al.: Lymphocyte subset abnormalities in multitransfused HIV-negative haemophilia A patients are not due to chronic hepatitis C virus infection. Br J Haematol 2000, 109:529–533.

    Article  PubMed  CAS  Google Scholar 

  24. Meijer K, Smid WM, Verspiek SP, et al.: Differences in immune response between HCV positive, HIV negative haemophilia A and B patients. Thromb Haemost 1998, 9:59–61.

    Google Scholar 

  25. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990, 99:1396–1400.

    PubMed  CAS  Google Scholar 

  26. Theodore D, Fried MW, Kleiner DE, et al.: Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004, 10:413–421. Many clinicians are reluctant to biopsy patients with hemophilia due to concern over bleeding-related complications, despite the growing contribution of ESLD to morbidity and mortality in this patient group. This consensus panel of experts concludes via literature review that biopsy is relatively safe, provided that adequate hemostasis is achieved prior to the procedure, and should be performed as part of routine evaluation of HCV-infected hemophiliacs.

    Article  PubMed  CAS  Google Scholar 

  27. Sterling RK, Lissen E, Clumeck N, et al.: Can routine noninvasive tests predict liver histology in HIV/HCV coinfection? Analysis of patients entering the AIDS PEGASYS Ribavirin International Coinfection Trial (APRICOT) [abstract 120]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  28. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  29. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  30. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355.

    PubMed  CAS  Google Scholar 

  31. Makris M, Preston FE, Triger DR, et al.: A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991, 78:1672–1677.

    PubMed  CAS  Google Scholar 

  32. Makris M, Preston FE, Triger DR, et al.: Interferon alfa for chronic hepatitis C in haemophiliacs. Gut 1993, 34:S121-S123.

    PubMed  CAS  Google Scholar 

  33. Rumi MG, Santagostino E, Morfini M, et al.: A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997, 89:3529–3533.

    PubMed  CAS  Google Scholar 

  34. Fried MW, Peter J, Hoots K, et al.: Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002, 6:967–972. This randomized, controlled U.S. trial compared IFN alpha and ribavirin to IFN alpha alone in hemophiliacs. SVR rates were lower than might be expected based on trials in the nonhemophilic population: 29% (16/56) versus 7% (4/57), respectively.

    Google Scholar 

  35. Santagostino E, De Filippi F, Rumi MG, et al.: Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 2004, 44:790–794.

    Article  PubMed  CAS  Google Scholar 

  36. Shire NJ, Sherman KE, Horn PS, Eyster E: Viral kinetic parameters and treatment response in HIV/HCV coinfected vs. HCV infected hemophiliacs. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  37. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438–450.

    Article  PubMed  CAS  Google Scholar 

  38. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459.

    Article  PubMed  CAS  Google Scholar 

  39. Perronne C, Carrat F, Bani-Sadr F, et al.: Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylatedinterferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  40. Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy. Science 1998, 282:103–107.

    Article  PubMed  CAS  Google Scholar 

  41. Sherman KE, Shire NJ, Rouster SD, et al.: Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virusinfected patients. Gastroenterology 2005, 28:313–327.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Digestive Diseases, University of Cincinnati, 231 Albert Sabin Way, PO Box 0595, 45267-0595, Cincinnati, OH, USA

    Norah J. Shire MPH

Authors
  1. Norah J. Shire MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth E. Sherman MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shire, N.J., Sherman, K.E. Hepatitis C Virus in patients with inherited bleeding disorders. Curr hepatitis rep 4, 87–91 (2005). https://doi.org/10.1007/s11901-005-0034-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-005-0034-0

Keywords

Search

Navigation